Trilafon - Perphenazine

Perphenazine (Trilafon). Perphenazine has a potency and side effect profile similar to other medium potency antipsychotics. 

Oral liquid concentrates are available for use in patients who can more easily swallow a liquid. These concentrates are light sensitive and dispensed in amber or opaque bottles to help protect the concentrate from light. They are administered mixed in liquids such as fruit juices, tomato juice, milk, or carbonated beverages. Semisolid foods, such as soups or puddingy, may also be used. Perphenazine (Trilafon) concentrate should not be mixed with beverages containing caffeine (coffee, cola), tea, or apple juice because of the risk of incompatibility. 

Paliperidone (Eivega) Perphenazine (Trilafon) Prochlorperazine (Compazine) Quetiapine (Seroquel, Seroquel XR)... 

Moban) olanzapine (Zyprexa) perphenazine (Trilafon) pimozide (Orap) quetiapine (Seroquel) risperidone (Risperdal) thioridazine (Mellaril) thiothixene (Navane) trifluoperazine (Stelazine) trifuluopromazine (Vesprin) ziprasidone (Geodon). 

Despite enormous hype to the contrary, it soon became apparent that these newer medications were no less harmful than the older ones. Studies showing a lower rate of adverse effects simply used comparatively lower doses (Smith, 2001). Given that these drugs are neither safer nor more effective than older drugs like perphenazine (Trilafon see the subsequent sections), and given that they cost a great deal more (Rosenheck et ah, 2006), this was another triumph of pharmaceutical marketing. 

In 2005, an NIMH multisite study called CATIE compared the older neuroleptic perphenazine (Trilafon) and atypical neuroleptics olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), and zipra-sidone (Geodon Lieberman et al., 2005a see also Nasrallah, 2007 Rosenheck et al., 2006 Weiden, 2007a). Phase I involved 1,460 patients diagnosed with schizophrenia initially randomly assigned in a doubleblind study to one of the five neuroleptics. The study lasted 18 months, with safety and tolerability outcomes evaluated at 1, 3, 6, 9, 12, 15, and 18 months. 

Note that perphenazine (Trilafon) is in the middle of the pack there was no statistical difference between it and the leader, olanzapine (Zy-prexa). But Zyprexa had the worst adverse effect profile (see subsequent sections). 

---